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Abstract: The objective of this study was to develop angiopoietin-1 (Ang1)-expressing 
  genetically modified human adipose tissue derived stem cells (hASCs) for myocardial therapy. 
For this, an efficient gene delivery system using recombinant baculovirus complexed with cell 
penetrating transactivating transcriptional activator TAT peptide/deoxyribonucleic acid nano-
particles (Bac-NP), through ionic interactions, was used. It was hypothesized that the hybrid 
  Bac-NP Ang1 system can efficiently transduce hASCs and induces favorable therapeutic effects 
when transplanted in vivo. To evaluate this hypothesis, a rat model with acute   myocardial infarc-
tion and intramyocardially transplanted Ang1-expressing hASCs (hASC-Ang1),   genetically 
modified by Bac-NP Ang1, was used. Ang1 is a crucial pro-angiogenic factor for vascular maturation 
and neovasculogenesis. The released hAng1 from hASC-Ang1 demonstrated profound mitotic 
and anti-apoptotic activities on endothelial cells and cardiomyocytes. The transplanted hASC-
Ang1 group showed higher cell retention compared to hASC and control groups. A significant 
increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts 
with hASC-Ang1 treatment compared to infarcted hearts treated with hASC or the untreated 
group. Furthermore, the hASC-Ang1 group showed significantly higher cardiac performance 
in echocardiography (ejection fraction 46.28% ± 6.3%, P , 0.001 versus control, n = 8) than 
the hASC group (36.35% ± 5.7%, P , 0.01, n = 8), 28 days post-infarction. The study identi-
fied Bac-NP complex as an advanced gene delivery vehicle for stem cells and demonstrated 
its potential to treat ischemic heart disease with high therapeutic index for combined stem 
cell-gene therapy strategy.
Keywords: combined stem cell-gene therapy, baculovirus, nanoparticle, myocardial therapy, 
angiogenesis, tissue engineering
Introduction
A promising therapeutic approach currently under intensive clinical trials is 
  mesenchymal stem cell (MSC) therapy for congestive heart diseases, which depends on 
several corroborated mechanisms, such as myocyte formation and neovascularization 
to improve cardiac function and attenuate ventricular remodeling.1,2 Despite promising 
initial results, such clinical application remains limited due to logistic, economic, and 
timing issues when harvesting autologous stem cells from elderly patients. Moreover, 
it has been reported that MSCs obtained from elderly donors and patients with diabetes 
or ischemic heart disease have a significantly reduced capacity for neovascularization, 
proliferation, and differentiation potential.3
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Delivering proangiogenic proteins, such as vascular 
endothelial growth factor (VEGF) and angiopoietin-1 (Ang1), 
using MSC-based gene therapy approaches are   currently 
being employed in recent studies as an alternative strategy 
to promote myocardial angiogenesis and regeneration.4–6 
However, the mammalian gene delivery vectors widely used 
in such studies have various drawbacks and severe safety 
concerns.7–9 These vectors are prone to integration into   coding 
regions of transcriptionally active genes, raising concerns 
about gene silencing and insertional mutagenesis. On the 
other hand, nonviral gene delivery systems are much safer 
for potential clinical applications, but are currently limited 
by low transfection efficiency and highly transient nature of 
expression with suboptimal level of transgene   expression. 
Unlike the aforementioned vectors, baculovirus (Bac) is an 
insect cell-originated viral vector that is considered non-
pathogenic to humans as they cannot replicate in   mammalian 
cells.9,10 The viral genome remains in episomal form within 
the nucleus and is degraded within mammalian cells over 
time, eliminating the chance of potential mutagenesis. They 
can efficiently transduce a wide range of mammalian cells 
with minimal cytotoxicity, including MSCs as shown in 
earlier studies, and reports confirm the safety of transplanting 
Bac-engineered MSCs into immunocompetent animals for 
cell-based gene therapy.9,11
The present study aimed to develop a hybrid nanodeliv-
ery system to genetically modify MSCs efficiently, utilizing 
the complementary strengths of Bac, such as relatively high 
transduction efficiency and easy scale-up, and transactivat-
ing transcriptional activator (TAT)/deoxyribonucleic acid 
(DNA) nanoparticles (NPs), such as low immunogenicity. 
TAT peptide sequence, obtained from the protein transduction 
domain of human immunodeficiency virus-1 responsible for 
nuclear import of human immunodeficiency virus genome, 
was modified here by incorporating histidine and cysteine 
residues for enhanced DNA transport, efficient cell penetra-
tion, cell vesicle escape, and transgene expression.12 The 
potential of this new system for direct gene therapy with 
cardiomyocytes has recently been demonstrated.13 Here, 
it was hypothesized that MSC transduction efficiency can 
also be significantly enhanced by this new system where the 
negatively charged Bac is coupled with positively charged 
endosomolytic histidine rich TAT peptide/DNA NPs, both 
carrying the transgene. For this, a unique pool of MSCs 
located within the adipose tissue was used, called adipose 
tissue-derived stem cells (ASCs), mainly because of their 
practical availability and pro-angiogenic, immunomodula-
tory, and other unique properties.14,15 Based on the positive 
efficacy data in disease-relevant animal models, ASCs have 
recently entered into their first clinical trial.16 In a recent 
intriguing study, Metzele et al reported that human ASCs 
(hASCs) can fuse to newborn rat heart cells to form new 
cardiomyocytes with several nuclei, which can beat when 
maintained in a culture environment.17 ASCs possess a natural 
ability to secrete VEGF, which overexpresses under hypoxic 
conditions in ischemic tissues.18
It has been reported that VEGF in cooperation with 
another angiogenic growth factor, Ang1, promotes significant 
neovascularization, and their combined action leads to a for-
mation of mature and functional vasculature.19–21 Thus, it was 
hypothesized that the secretion of Ang1 along with   naturally 
releasing VEGF from the genetically modified ASCs, 
together with their inherent transdifferentiation abilities to 
cardiomyocytes, can induce a superior synergistic therapeu-
tic effect for myocardial regeneration therapy. Additionally, 
acute myocardial infarction also induces a high circulating 
endogenous serum VEGF state.22 With these rationales, Ang1 
complementary DNA-carrying recombinant Bac and TAT 
NPs were generated, a self-assembled binary nanocomplex 
was prepared by hybridizing the two, and its efficiency to 
express functionally active Ang1 was determined using 
optimized transduction protocol with hASCs. The in vivo 
efficacy of the formulated nanobiohybrid (Bac-NP) system 
for combined stem cell-gene therapy applications was also 
evaluated using human Ang1 (hAng1)-expressing genetically 
modified hASCs for myocardial therapy using an immuno-
competent infarcted rat heart model. A schematic presenta-
tion of the entire procedure is demonstrated in Figure 1.
Methods and materials
Cell culture and preparation  
of Bac gene delivery complex
Human ASCs (n = 1 male donor) were obtained from Invitro-
gen Life Technologies (Carlsbad, CA) and cultured in Gibco® 
  Dulbecco’s Modified Eagle Medium (Invitrogen) supplemented 
with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY). 
The cells were routinely maintained as stationary cultures in 
75 cm2 tissue culture flasks (Corning, MA) and incubated at 
37°C in a controlled environment with an air atmosphere of 
5% carbon dioxide. Human umbilical vein endothelial cells 
(HUVECs) (ScienCell Research Laboratories, Carlsbad, CA) 
were cultured and expanded on tissue culture flasks according 
to the supplier’s instructions. They were cultured in endothe-
lial cell medium (ScienCell) supplemented with 5% FBS and 
placed in an incubator containing 5%   carbon dioxide at 37°C. 
H9c2 myogenic cell line, derived from   embryonic rat heart 
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  ventricles, was obtained from   American Type Culture   Collection 
(CRL-1446; Manassas, VA) and cultured in   Dulbecco’s Modi-
fied Eagle Medium supplemented with 10% FBS. The cells 
were routinely maintained as stationary cultures in flasks, 
incubated at 37°C in a controlled   environment with 5% carbon 
dioxide. Sf 9 insect cells (Invitrogen) were maintained at 27°C 
in SF-900™ III serum free medium (Invitrogen). The cells 
were maintained in exponential growth phase and subcultured 
twice per week. Larger volumes were prepared in shaker flasks 
(Erlenmeyer; Corning Life Sciences, Lowell, MA) which were 
agitated at 120 rpm in an incubator shaker as mentioned in 
earlier studies.11
Generation of LacZ and Ang1 gene-carrying recombinant 
Bac and their subsequent hybridization with NPs to form 
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Figure  1  Schematic  representation  of  the  overall  scheme:  generation  of  recombinant  baculovirus  (BacAng1),  preparation  of  hybridized  baculovirus  with  TAT/DNA 
nanoparticles, in vitro human adipose tissue-derived stem cell transduction, and in vivo investigation using direct intramyocardial transplantation of ASC-Ang1 using a rat 
model with acute myocardial infarction. Transmission electronic microscopic pictures of baculovirus, nanoparticle, and baculovirus-nanoparticle complex shown in subsets 
confirm the formation of the nanocomplex (in white arrows).
Abbreviations:  ASC-Ang1,  angiopoietin-1-expressing  adipose  tissue-derived  stem  cells;  BacAng1,  angiopoietin-1-carrying  baculovirus;  Bac-NPAng1,  angiopoietin-1-
carrying  baculovirus-nanoparticle  complex;  DNA,  deoxyribonucleic  acid;  ELISA,  enzyme-linked  immunosorbent  assay;  NPAng1,  angiopoietin-1-carrying  nanoparticles; 
TAT, transactivating transcriptional activator.International Journal of Nanomedicine 2012:7
Bac-NP Ang1 and Bac-NPLacz were performed using protocol 
as mentioned in earlier work.13
Detection of hAng1 expressed  
by the transduced hASCs: enzyme- 
linked immunosorbent assay (ELISA)  
and immunofluorostaining
In order to evaluate the transduction efficiency of Bac-NP on 
hASCs and compare it with free Bac and NP gene system, 
NP Ang1, BacAng1, and Bac-NP Ang1 at multiplicity of infection 
(MOI; defined as plaque forming units per cell) of 200 were 
used. hASCs were seeded in six-well plates at 0.5 × 106 
cells/well and incubated overnight at 5% carbon dioxide and 
37°C. Following this, an appropriate volume of the nanocom-
plexes suspended in phosphate buffered saline (PBS; Life 
  Technologies, Burlington, ON, Canada) was added to each 
well and incubated for 4 hours. Following this, the transduc-
tion solution was replaced with fresh media and grown in a 
cell culture incubator. Conditioned media were collected every 
alternate day for 21 days and stored at −80°C for Ang1 ELISA 
(R&D Systems, Inc,   Minneapolis, MN) analysis using standard 
procedure provided by the   manufacturer.13 To detect the Ang1 
expressed within the transduced cells, in another set of experi-
ments, hASCs transduced with NP Ang1, BacAng1, and Bac-NP Ang1 
or nontreated controls were grown on glass microscope slides 
for 96 hours. After washing with PBS, the cells were fixed 
with −20°C methanol for 10 minutes followed by immuno-
staining as mentioned elsewhere.23 Briefly, after blocking for 
1 hour with 10% donkey serum (Santa Cruz Biotechnology, 
Santa Cruz, CA), the cells were incubated overnight at 37°C 
with 1:50 dilution of goat anti-hAng1 (Santa Cruz Biotech-
nology) primary antibodies. On the second day, the cells were 
thoroughly washed with wash buffer. The cells were incu-
bated with donkey anti-goat immunoglobulin G-tetramethyl 
rhodamine isothiocyanate (Santa Cruz Biotechnology) with 
1:200 dilutions for 1 hour. The proportions and intensities of 
tetramethyl rhodamine isothiocyanate-positive hASCs, as seen 
under fluorescence microscope (Eclipse TE2000U; Nikon Cor-
poration, Tokyo, Japan), gave a qualitative idea of the relative 
amount of cellular Ang1 expressed due to transgene delivery 
by the different delivery systems.
Cell proliferation and viability assay
For the cell proliferation assay, 2 × 104 HUVEC cells/
well were seeded in triplicate for each sample in 96-well 
plates. After 8 hours of culturing, the cells were washed 
twice with PBS and 200 µL of conditioned media from 
  nontransduced hASCs, Bac-NPLacZ-transduced hASCs, 
Bac-NP Ang1-transduced hASCs, and Bac-NP Ang1-transduced 
hASCs supplemented with anti-hAng1 antibodies were 
added to the corresponding set of wells. After 96 hours, 
absorbance was measured at 490 nm using CellTiter 
96®   AQueous Non-  Radioactive Cell Proliferation Assay 
  (Promega, Fitchburg, WI) in a Victor3 Multi Label Plate 
Counter (Perkin Elmer, Montreal, QC, Canada).24 In a similar 
way, cardiomyocyte cell viabilities under oxidative stress in 
groups treated with different conditioned media were mea-
sured as described later in the study, using the same assay. 
The experiment was performed in triplicate.
Wound healing assay with HUVECs
In order to check the wound healing potential of released 
Ang1, HUVECs were seeded into 24-well plates and grown 
to confluency. After 24 hours of serum starvation (1% FBS), 
lesions were made in the monolayer using a cell scraper.13 
Cells were rinsed with PBS, and then incubated with the hASC 
cardiomyocytes from different experimental groups (NP Ang1, 
BacAng1, and Bac-NP Ang1) for 24 hours.   Cardiomyocytes 
from untransduced hASCs were used as control. To confirm 
the beneficial effect of Ang1 in particular, cardiomyocytes 
from Bac-NP Ang1 group were preincubated with anti-Ang1 
neutralizing antibody (R&D Systems; 1 µg/mL) for 30 min-
utes before being added to the wells. Cells were fixed with 
4% paraformaldehyde (Sigma-Aldrich, St Louis, MO) after 
24 hours and the number of cells which had moved across the 
starting scratched lines were measured for all groups. Three 
fields were analyzed for each well at 200× magnification under 
bright field settings of the microscope mentioned earlier.
Apoptosis assay using cardiomyocytes
H9c2 cells were seeded in 96-well microtiter plates at a   density 
of 2 × 104 cells/well and cultured overnight. The media was 
replaced with cardiomyocytes from different treatment groups 
and oxidative stress was induced by adding 200 µM hydro-
gen peroxide to the media as described   elsewhere.25 After 
6 hours, the apoptotic cells were detected by tracking the loss 
of mitochondrial membrane potential using MitoCapture™ 
Apoptosis Detection Kit   (BioVision, Inc, Mountain View, 
CA) cell staining cationic dye, according to the manufacturer’s 
protocol, which fluoresces differently in healthy and apoptotic 
cells under fluorescence microscope (488-nm and 543-nm 
excitation filters). The red emission of the dye is due to a 
potential-dependent aggregation in the mitochondria reflecting 
normal membrane   potential and the green fluorescence detects 
the monomeric form of MitoCapture, appearing in the cyto-
sol after mitochondrial membrane depolarization.26 For each 
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experimental group, total cell number was counted and related 
to the number of cells that displayed fluorescence. In a similar 
way, after oxidative stress of 6 hours, the cell viabilities were 
also checked using CellTiter 96 assay as mentioned above.
In vivo studies in myocardially  
infarcted rat model
Immunocompetent female Lewis rats (200–250 g; Charles 
River Laboratories, Senneville, QC, Canada) were used. All 
procedures were in compliance with the Guide for the Care 
and Use of Laboratory Animals (National Institutes of Health 
publication 85-23) and the Guide to the Care and Use of 
Experimental Animals of the Canadian Council on Animal 
Care. Female Lewis rats were anesthetized. The rats were intu-
bated with an 18-gauge catheter and mechanically ventilated 
(Harvard Ventilator 683; Harvard Apparatus, St Laurent, QC, 
Canada) at 80 breaths/minute. Anesthesia was maintained with 
3% isoflurane. A left thoracotomy was performed through the 
fourth intercostal space to expose the left ventricle. The left 
coronary artery was ligated 2 mm from its origin with a 7-0 
polypropylene suture (Ethicon, Inc, Somerville, NJ) using 
standard protocol.13 The ischemic myocardial segment rapidly 
became identifiable through its pallor. Fifteen minutes after 
ligation of the artery, intramyocardial injections were given. In 
the control group with no hASC (n = 8), 300 µL of the culture 
medium was divided into three equal periinfarct left ventricular 
intramyocardial injections using a 27 gauge needle. In the hASC 
group (n = 8), the same procedure was repeated using culture 
medium containing 3 × 106 hASCs, while the group hASC-
Ang1 (n = 8) received the same number of cells transduced 
with Bac-NP Ang1 (MOI: 200) suspended in culture medium.
To detect the transgene expression in transplanted cells, 
three animals underwent the same experimental procedure as 
described above, followed by injection of three million cells 
transduced with Bac-NPLacZ (MOI: 200). Three days post-
transplantation, LacZ expression was detected in histological 
samples using a standard staining LacZ staining procedure.13
Detection of transplanted male  
hASCs in female rat hearts:  
polymerase chain reaction (PCR)  
analysis for human Y chromosome
In order to detect the transplanted hASCs from the male 
donor in heart tissue, samples from groups with no hASC 
(n = 6), hASC (n = 6), and hASC-Ang1 (n = 6) were taken. 
After 3 days and 28 days post-injection, three animals from 
each group were sacrificed and heart tissue samples were 
snap frozen. PCR analysis was done on the extracted DNA 
samples to confirm the survival of the implanted gender-
mismatched cells in the hearts using standard procedure 
followed in earlier studies.27 Briefly, equal amounts of DNA 
were extracted from peri-infarct portions of the ventricular 
heart in each group and PCR analysis was done to confirm 
the survival of the implanted gender-mismatched cells in 
the hearts 3 days and 28 days post-operation. Genomic 
DNA was purified using DNeasy (QIAGEN, Valencia, CA) 
according to the manufacturer’s instructions, and the pres-
ence of living male cells in female hearts was confirmed 
by targeting a specific microsatellite sequence within the 
Y chromosome (DYS390). The primer pairs used were for-
ward primer 5′TATATTTTACACATTTTTGGGCC3′ and 
reverse primer 5′TGACAGTAAAATGAACACATTGC3′ 
with product length of 250 base pairs.
Scar area analysis: myocardial infarct size
Twenty-eight days post-operation, rats were deeply anes-
thetized and sacrificed by rapid excision of the heart. The 
excised hearts were immediately soaked in cold saline 
to remove excess blood from the ventricles and fixed in 
neutral-buffered 4% formalin. Paraffin embedded samples 
were sectioned at 5 µm, and Masson’s trichrome staining 
(Diagnostic BioSystems, Pleasanton, CA) was performed 
to delineate scar tissue (blue color) from the total area of 
myocardium.22,28 Masson’s trichrome-stained section images 
were analyzed by ImageJ 1.41 software (National Institutes 
of Health, Bethesda, MA). Infarct area, epicardial and endo-
cardial length of infarction, and ventricular and septal wall 
thickness were calculated and expressed as a percentage.
Immunohistochemistry for detecting 
neovascularization
Neovascularization was evaluated by analyzing capil-
lary and arteriole density in the periinfarct area. For 
this, immunohistochemical staining was performed with 
anti-PECAM (Santa Cruz Biotechnology) for identifica-
tion of endothelial cells and antismooth muscle α-actin 
(Santa Cruz   Biotechnology) for tracing the smooth muscle 
cells, as described   elsewhere.22 Briefly, for measurement 
of capillary density, five fields in the periinfarct area were 
imaged with 200× magnification and average numbers of 
capillaries ,10 µm in diameter were counted. Capillary 
density was quantified as (mean total PECAM-positive 
microvessels)/mm2 using three tissue sections spanning the 
periinfarct tissue region of each animal. Similarly, arteriole 
densities were quantified as (mean total smooth muscle 
α-actin-positive microvessels)/mm2.
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Transthoracic echocardiography
Transthoracic echocardiography was performed on all 
surviving animals in rat groups treated with hASC (n = 8), 
hASC-Ang1 (n = 8), and untreated control (n = 8) on day 3, 
day 14, and day 28 post-infarction. Echocardiograms were 
obtained with a commercially available system (Titan®; 
SonoSite, Inc, Bothell, WA) equipped with a 15-MHz 
transducer. After sedating the animals with 2% isoflurane, 
echocardiography was performed according to the American 
Society of Echocardiology leading-edge method.27 Briefly, 
parasternal long- and short-axis views were obtained with 
both M-mode and two-dimensional images. Left ventricular 
end-diastolic and end-systolic diameters were measured 
with M-mode tracings between the anterior and posterior 
walls from the short-axis view just below the level of the 
papillary muscles of the mitral valve. Two images on aver-
age were obtained in each view and averaged over three 
consecutive cardiac cycles. Left ventricular end-diastolic 
volume was calculated as 7.0 × left ventricular end-diastolic 
diameter3/(2.4 + left ventricular end-diastolic diameter), and 
left ventricular end-systolic volume as 7.0 × left ventricular 
end-systolic diameter3/(2.4 + left ventricular end-systolic 
diameter). Ejection fraction was estimated as (left ventricular 
end-diastolic volume – left ventricular end-systolic volume)/
left ventricular end-diastolic volume.
Statistical analysis
Quantitative variables are presented as mean ± standard 
deviation from independent experiments as described in the 
figure legends. Statistics were performed using two-way 
and/or one-way analysis of variance by Bonferroni’s mul-
tiple comparison post hoc test. All statistical analyses were 
performed with GraphPad Prism (v 5.0; GraphPad Software, 
Inc, La Jolla, CA). P , 0.05 was considered significant.
Results
Bac-Ang1-transduced hASCs  
can efficiently release hAng1
Released Ang1 from the transduced hASCs was analyzed 
at protein level by hAng1 ELISA. As shown in Fig-
ure 2A–C, hAng1 expression was detected from day one 
post-  transduction until day 21 with regular intervals for all 
groups (NP Ang1, BacAng1, and Bac-NP Ang1). The highest expres-
sion was seen on day four with the gene delivery systems. 
  However, highest expression was achieved with Bac-NP Ang1 
(18.5 ± 1.2 ng/106 cells), which stayed persistently higher 
than other groups all throughout the experimental period. 
Moreover, cellular Ang1 expression, demonstrated by 
tetramethyl rhodamine isothiocyanate-stained cells 96 hours 
post-transduction, was shown to be highest in the Bac-
NP Ang1-treated group as compared to NP Ang1 and BacAng1 
(Figure 2D–G). ELISA and immunostaining analysis con-
firmed that Bac-NP Ang1 was a superior gene delivery vehicle 
than free BacAng1 and NP Ang1 alone, and was able to express 
higher amounts of hAng1 transgene at both extracellular 
and intracellular level.
Biologic activity of the secreted hAng1 
on vascular endothelial cells
To confirm the functionality of  the expressed hAng1, HUVEC 
proliferation assay was performed using the conditioned 
media from Bac-NPAng1-transduced hASCs and compared 
with that of control Bac-NPLacZ-transduced hASCs and 
untransduced hASCs. As reported in Figure 3A, the samples 
with high Ang1 concentrations, ie, from cardiomyocytes of 
Bac-NP Ang1-transduced hASCs, significantly increased the 
proliferation rate of HUVECs (2.67 × 104 cells compared to 
1.85 × 104 cells in Bac-NPLacZ cardiomyocytes, 1.89 × 104 in 
control nontransduced cardiomyocytes, and 1.59 × 104 cells 
in cardiomyocytes with antibody – 2 × 104 cells were taken 
as the initial density).
Furthermore, the ability of cardiomyocytes (containing 
secreted hAng1) to increase HUVEC wound healing in a 
monolayer was tested. As depicted in Figure 3B and C, 
stimulation of wounded HUVEC monolayer with cardio-
myocytes from Bac-NP Ang1 (33.3% ± 2.0%) induced a sig-
nificant reduction of wound compared with the unstimulated 
control (16.8% ± 1.4%) and cardiomyocytes from Bac-NPLacZ 
(16.1% ± 4.2%). Thus, consistent with mitotic assay results, 
Bac-NP Ang1 showed highest healing potential, indicating 
that efficient overexpression of Ang1 is one of the deter-
mining factors for inducing substantial biological effects. 
  Preincubation of cardiomyocytes with neutralizing anti-Ang1 
antibodies completely inhibited Bac-NP Ang1 cardiomyocyte-
induced wound healing, clearly suggesting that chemotactic 
signals from hAng1 are essential for this effect.
Biologic activity of the secreted  
hAng1 on cardiomyocytes
In order to assess whether the secreted hAng1 have a pro-
tective effect on cardiomyocytes under oxidative stress, the 
treated H9c2 cells from different groups underwent cell 
viability studies after 6 hours oxidative stress using hydrogen 
peroxide. The data in Figure 4A show that cardiomyocytes 
from Bac-NP Ang1 were able to significantly reduce cell death 
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compared to Bac-NPLacZ and Bac-NP Ang1+antibody (1.82 ± 0.02 
versus 1.04 ± 0.04 versus 0.93 ± 0.08), taking a normalized 
value of  the cell number in the untreated control group as 1.0. 
As positive control, cells with no oxidative stress were taken 
which showed a viability amount of 1.82 ± 0.02.
Furthermore, the antiapoptotic effect of the released 
hAng1 on cardiomyocytes under oxidative stress was 
examined and quantified by MitoCapture cell staining 
(Figure 4B and C). Cultivation of H9c2 cardiomyocytes 
under hydrogen peroxide-induced oxidative stress for 6 hours 
provoked a strong apoptotic response with 60.7% ± 3.7% of 
apoptotic cells in the untransduced control cardiomyocyte 
group.   Addition of cardiomyocytes from Bac-NP Ang1 hASCs 
strongly   suppressed cardiomyocyte apoptosis (24.1% ± 2.9%) 
in comparison to other groups, which did not show any sig-
nificant effect.
hASCs can survive and efficiently  
express their transgene in vivo
To analyze whether the xenotransplanted genetically modi-
fied hASCs were able to survive and express the transgene 
in the rat heart, hearts (n = 3) were myocardially infarcted 
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Figure 2 Time course profile of human angiopoietin-1 expression by human adipose tissue-derived stem cells transduced with (A) NPAng1, (B) BacAng1, and (C) Bac-NPAng1. 
NPLacZ, BacLacZ, and Bac-NPLacZ were used as control groups. Quantification of secretory human angiopoietin-1 expression in the media by enzyme-linked immunosorbent assay 
was done at different time points after human adipose tissue-derived stem cell transduction in different media. Results are mean ± standard deviation for three independent 
experiments. Fluorescent immunostaining of human adipose tissue-derived stem cells transduced with (D) untreated control, (E) NPAng1, (F) BacAng1, and (G) Bac-NPAng1 
to detect intracellular human angiopoietin-1 expression. Human angiopoietin-1 expression was visualized by tetramethyl rhodamine isothiocyanate-conjugated secondary 
antibodies (red, tetramethyl rhodamine isothiocyanate; blue, 4′,6-diamidino-2-phenylindole).
Abbreviations:  Ang1,  angiopoietin-1;  BacAng1,  angiopoietin-1-carrying  baculovirus;  BacLacZ,  LacZ-carrying  baculovirus;  Bac-NPAng1,  angiopoietin-1-carrying  baculovirus-
nanoparticle complex; Bac-NPLacZ, LacZ-carrying baculovirus-nanoparticle complex; NPAng1, angiopoietin-1-carrying nanoparticles; NPLacZ, LacZ-carrying nanoparticles.International Journal of Nanomedicine 2012:7
and injected with hASCs transduced with Bac-NPLacZ in the 
left ventricular region, as described earlier. Three days post-
transplantation, the rat hearts were harvested and ventricular 
tissue samples were stained with X-gal in order to trace the 
transplanted LacZ-expressing hASCs in the peri-infarct region 
of the heart. Figure 5A confirms that the transplanted cells 
were able to survive and express the transgene in the heart.
Higher retention of implanted  
hASC-Ang1 in rat myocardium
After confirming transplant survival and transgene   expression, 
the effect of Ang1-expressing hASCs compared to normal 
hASCs on cardiac cellular transplant retention was further 
explored. Three groups (no hASC [n = 6], hASC [n = 6], 
and hASC-Ang1 [n = 6]) were taken as mentioned earlier. 
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Figure 3 (A) Proliferation of HUVECs grown in the presence of cardiomyocytes from Bac-NPLacZ, Bac-NPAng1, and nontreated control human adipose tissue-derived stem 
cells. In another group, cardiomyocytes from human adipose tissue-derived stem cells transduced with Bac-NPAng1 were pretreated with antibodies against angiopoietin-1 
(1 µg/mL). Initial seeding density was 2 × 104 cells/well. Proliferation was measured by a colorimetric assay after 96 hours of growth. Mean ± standard deviation from three 
experiments are shown. (B) Human angiopoietin-1 induces migration of endothelial cells in a wound healing assay. HUVEC monolayer was wounded with cell scraper and 
treated with cardiomyocytes from human adipose tissue-derived stem cells transduced with Bac-NPLacZ and Bac-NPAng1. As another group, cardiomyocytes from Bac-NPAng1 
were previously treated with an excess of neutralizing anti-human angiopoietin-1 antibodies (1 µg/mL) before performing the wound healing assay. Cardiomyocytes from 
untreated/nontransduced cells were used as the control group. (C) HUVECs were photographed (200×) after 24 hours treatment and percentage of scratched area (which 
was initially free of cells, marked by the white dotted border line) covered by the migrated cells was analyzed using ImageJ 1.41 software (National Institutes of Health, 
Bethesda, MA) as presented in (B).
Notes: Mean ± standard deviation from three independent experiments is shown. One-way analysis of variance: statistically significant differences between groups compared 
to unstimulated control are indicated as ***P , 0.001.
Abbreviations:  Bac-NPAng1,  angiopoietin-1-carrying  baculovirus-nanoparticle  complex;  Bac-NPLacZ,  LacZ-carrying  baculovirus-nanoparticle  complex;  ctrl,  control; 
HUVEC, human umbilical vein endothelial cell.International Journal of Nanomedicine 2012:7
Three days and 28 days post-injection, three animals from 
each group were sacrificed for PCR analysis.
DNA was extracted from the injected sites of the 
heart tissues to detect the presence of Y chromosome of 
transplanted male hASC using standard PCR. The gel 
  electrophoresis of the PCR products shows a clear distinc-
tion in band   intensities of hASC-Ang1 and normal hASCs 
(Figure 5B). The hASC-Ang1 group showed around 1.72 
times higher retention of viable transplanted cells in the 
heart in comparison to normal hASCs (0.55 times versus 
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Figure 4 (A) Quantification of viable H9c2 cells when exposed to oxidative stress. H9c2 cells under different human adipose tissue-derived stem cell cardiomyocytes 
(control nontransduced, Bac-NPLacZ, Bac-NPAng1, and Bac-NPAng1 with antibody against angiopoietin-1) were exposed to 200 µmol/L hydrogen peroxide for 6 hours. This 
was followed by cell viability analysis. The viabilities of H9c2 cells in all groups were normalized to that of control untreated. (B) Under the same conditions, quantification 
of H9c2 cardiomyocyte apoptosis was performed by detecting the intact and disrupted mitochondrial membrane potential using MitoCapture probe. After oxidatives 
insult, MitoCapture staining was performed and the percentage of apoptotic cells was calculated for each group. (C) Cells with mitochondrial damage show diffuse green 
fluorescence, whereas cells with intact mitochondrial membrane potential exhibit red fluorescence (magnification 200×). Cells without oxidative stress were taken as positive 
control. Arrows indicate the apoptotic cells. Data confirm the human angiopoietin-1 released from human adipose tissue-derived stem cells transduced with Bac-NPAng1 
are functionally active and can significantly inhibit cardiomyocyte cell death and apoptosis induced by hypoxic condition.
Notes: The graphs represent the mean ± standard deviation from three independent experiments. Analysis of variance: statistically significant differences between groups 
compared to control untreated (cardiomyocytes) are indicated. ***P , 0.001.
Abbreviations: Bac-NPAng1, angiopoietin-1-carrying baculovirus-nanoparticle complex; Bac-NPLacZ, LacZ-carrying baculovirus-nanoparticle complex; CM, cardiomyocytes; 
ctrl, control.International Journal of Nanomedicine 2012:7
0.32 times, taking initial 3-day band intensity as 1.0; 
P , 0.05) as quantified by relative band intensities using 
ImageJ software. This semiquantitative analysis indicates 
that a much higher number of cells were able to survive 
the transplantation when they were genetically modified to 
express Ang1 protein.
Bac-Ang1 hASCs can significantly attenuate 
scar area formation in infarcted heart
Macroscopic views of Masson’s trichrome stained heart 
  sections are shown in Figure 6A. In both the control and cell 
treated groups, positively stained fibrous infarct areas were 
clearly observed in the heart 28 days after   myocardial infarction. 
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Figure 5 (A) Detection of transgene expression (LacZ) in baculovirus transduced hASCs transplanted in the myocardium. (i) Three million cells were transduced with 
Bac-NPLacZ (multiplicity of infection: 200) and intramyocardially injected in the left ventricular myocardium. (ii) Three days post-transplantation, hearts (n = 3) were harvested 
and traced for LacZ expression. (iii) Histological analysis of ventricular portion (200×: stained with eosin) shows the transplanted cells expressing the LacZ. Arrows show 
the transplanted stained hASC-LacZ cells in the periinfarct ventricle region. (B) Higher retention of hASC-Ang1 compared to only hASCs in the left ventricular myocardium 
28 days post-transplantation. (i) Polymerase chain reaction products (250 base pairs) specific for the human Y chromosome (DYS390 sequence) as detected in 2% agarose 
gel. There were clear distinct bands in group hASC-Ang1 (Lane 1 and 1’) and group hASC (Lane 2 and 2’) in all female rat hearts both on day three and day 28, while these 
bands were absent in no hASC control group (Lane 3 and 3′). Note that these band intensities were much lower in day 28 compared to day three, with group hASC having 
the least intensity. Representative polymerase chain reaction products from each group are shown here. (ii) ImageJ 1.41 software (National Institutes of Health, Bethesda, 
MA) analysis of the band intensities show the hASC group has a mean of 0.32 times (n = 3) and group hASC-Ang1 has a mean of 0.55 times (n = 3) band intensities, taking 
the band intensity of group hASC on day three as 1.0.
Notes: Two-way analysis of variance: F = 34.86, P = 0.0004 (treatment groups); F = 974.0, P , 0.0001 (day); F = 49.41, P = 0.0001 (interaction); ***P , 0.001 versus 
day-matched control hASC.
Abbreviations: Bac-NPLacZ, LacZ-carrying baculovirus-nanoparticle complex; hASC, human adipose tissue-derived cell; hASC-Ang1, angiopoietin-1-expressing human 
adipose tissue-derived cell; hASC-LacZ, LacZ-expressing human adipose tissue-derived cell; NTC, no template control for the polymerase chain reaction experiment.International Journal of Nanomedicine 2012:7
Thin infarcts and left ventricular wall with dilated left ventricu-
lar cavity were observed in the control hearts. On the other 
hand, the hearts in the cell treated groups had significantly 
lesser infarct areas (Figure 6B: 13.0% ± 3.1% for hASC-Ang1, 
31.5% ± 5.0% for hASCs, and 38.0% ± 3.3% for control; 
P , 0.01) and higher left ventricular wall thickness (Figure 6C: 
2.53 ± 0.19 mm for hASC-Ang1, 1.44 ± 0.24 mm for hASCs, 
and 0.91 ± 0.07 mm for control; P , 0.001) than the control 
heart. A total of 24 rats were analyzed for the determination 
of infarct size (no hASC control [n = 8], hASCs [n = 8], and 
hASC-Ang1 [n = 8]). Infarct size and wall thickness in the 
left ventricles at the section of the middle point between liga-
tion and apex were measured as described elsewhere.22 There 
was also a significant improvement in the group treated with 
hASC-Ang1 compared to hASCs group (P , 0.001) with 
respect to the percentage left ventricle infarct area and left 
ventricle infarct wall thickness.
Ang1-expressing hASCs induce 
angiogenesis and arteriogenesis
Reporting the significant attenuation of scar area with Ang1-
expressing hASCs in the last section, attempts were made 
to understand whether it was only the paracrine effect of the 
hASCs or a combinatorial effect of hASC-released Ang1 and 
paracrine factors which was responsible for the improvement. 
For this, the neovasculature formation in the periinfarct area 
was assessed by detecting angiogenesis and arteriogenesis 
densities (Figure 7). Indeed, a significant improvement was 
seen in angiogenesis in the hASC and hASC-Ang1 groups 
compared to the control (201 ± 25/mm2 for hASC-Ang1, 
174 ± 14/mm2 for hASCs, and 141.5 ± 6/mm2 for   control; 
P , 0.01). Moreover, the hASC-Ang1 group showed signifi-
cantly higher capillary density compared to hASC. Similar 
results were obtained with arteriole density in the hASC-
Ang1 group (12.25 ± 2.4/mm2 for hASC-Ang1, 9.5 ± 1.8/mm2 
for hASCs, and 6.5 ± 1.32/mm2 for control; P , 0.05), with 
the hASC-Ang1 group showing significantly higher arteriole 
density compared to hASC.
Significantly improved cardiac function  
is detected in hASC-Ang1-treated  
infarcted heart
To investigate if the reduction of scar area after stem cell 
therapy results in improved heart function, the ejection 
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Figure 6 (A) Histomorphometric analysis of infarct ventricular scar area. (i–iv) Representative images of left ventricle myocardial sections stained with Masson’s trichrome 
show the markedly decreased cardiac fibrosis after hASC and hASC-Ang1 transplantations 28 days post-infarction compared to the control. The blue area represents 
extracellular matrix deposition in the scar tissue and the red area represents the myocardium. (B) Semiquantitative analysis of the images of the stained collagen fractions in 
the infarct region, using ImageJ 1.41 software (National Institutes of Health, Bethesda, MA), show that hASC and hASC-Ang1 transplantations significantly decreased cardiac 
fibrosis compared to untreated group (n = 8) in terms of percent infarction size in left ventricular wall. (C) Moreover, hASC and hASC-Ang1 groups have significantly thicker 
left ventricular walls than untreated group. In both analyses, hASC-Ang1 treatment proved to be significantly better than hASC treatment.
Notes: Data expressed as mean ± standard deviation. One-way analysis of variance: (B) F = 101.3, P , 0.0001 and (C) F = 166.1, P , 0.0001 (treatment groups). Statistically 
significant differences between groups compared to control no hASC are indicated as ***P , 0.001; **P , 0.01; *P , 0.05. Significant difference between hASC and hASC-
Ang1 is indicated by †P , 0.001.
Abbreviations: hASC, human adipose tissue-derived cell; hASC-Ang1, angiopoietin-1-expressing human adipose tissue-derived cell; ctrl, control.International Journal of Nanomedicine 2012:7
fraction in a rat model of myocardial infarction at   different 
time periods (days three, 14, and 28) was monitored. 
  Ejection fraction of all groups was around 30% on day 
three post-infarction, indicating successful acute myocar-
dial infarction in all groups.27 As presented in Figure 8, 
there were significant improvements in ejection fraction 
in groups treated with hASC-Ang1 and hASCs compared 
to the control group on day 14 and day 28, although there 
were no significant differences between the groups on day 
three post-infarction (P . 0.05). In addition, the hASC-Ang1 
treated group showed a significantly greater increase in ejec-
tion fraction as compared to hASC-treated groups on day 14 
(44.78% ± 6.14% versus 37.1% ± 4.9%; P , 0.01) and day 
28 (46.28% ± 6.3% versus 36.35% ± 5.77%; P , 0.01). Thus, 
analysis using echocardiographic ejection fraction data sug-
gests that hASC-Ang1 can be a better alternative to hASCs to 
improve cardiac function after acute myocardial damage.
Discussion
Cardiovascular and ischemic heart disease is a major 
health concern in both developing and industrialized 
countries. Although different gene therapy approaches are 
being employed to treat the disease, clinical trials showed 
  limited results suggesting the need for a better gene therapy 
  strategy.29 It has been demonstrated in small animals, that 
ASCs induce wound healing effects in damaged ischemic 
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Figure 7 Angiogenesis and arteriogenesis in the periinfarct area. Immunohistological staining of CD31 to detect endothelial cells in (A) no hASC, (B) hASC, and (C) 
hASC-Ang1 groups. Immunohistological staining of smooth muscle α-actin for smooth muscle cells in (D) no hASC, (E) hASC, and (F) hASC-Ang1 groups. Quantification of   
(G) capillary and (H) arteriole density.
Notes: Data are expressed as mean ± standard deviation. One-way analysis of variance: (G) F = 24.86, P , 0.0001 and (H) F = 18.48, P , 0.0001 (treatment groups). 
Statistically significant differences between groups compared to control no hASC are indicated as ***P , 0.001; **P , 0.01; *P , 0.05. Significant difference between hASC 
and hASC-Ang1 is indicated by †.
Abbreviations: hASC, human adipose tissue-derived cell; hASC-Ang1, angiopoietin-1-expressing human adipose tissue-derived cell; ctrl, control.International Journal of Nanomedicine 2012:7
tissues mainly through proangiogenic paracrine mechanism 
followed by neovascularization, local recruitment of progeni-
tor cells, and exhibition of cardiomyocyte-like properties.17,30 
Moreover, ASCs secrete VEGF which has a favorable impact 
on myocardial neovascularization, tissue perfusion, and 
contractile performance. In addition, a larger number of 
ASCs can be easily harvested using noninvasive standard 
fat extraction techniques, which is of immense importance 
under clinical settings because of their ready availability.14,18 
Most importantly, as allogeneic hASCs can be easily obtained 
from young healthy donors, they could be of great value in 
elderly patients with advanced diseases, where their own 
ASCs could be dysfunctional.
The initial step involved the development of a recombi-
nant Bac carrying Ang1 and assessing its potential for direct 
gene therapy for efficient myocardial neoangiogenesis as 
reported in previous work.13 As the next step, the present 
study further explored its potential for stem cell-based gene 
therapy, apart from direct gene therapy. The present study 
reports for the first time, the angiogenic potential of this 
newly formulated hybrid nanodelivery system composed of 
vascular gene-carrying recombinant Bac armed with nonco-
valently conjugated TAT/DNA NPs for stem cell-based gene 
therapy. As stem cells are known to have a natural potential 
for cardiovascular therapies, complementing them with rapid 
Ang1 overexpression can further improve their efficacy. The 
present work illustrates this hypothesis in a rat model with 
acute myocardial infarction. Moreover, this is the first study 
to report the potential of recombinant Bac to genetically 
modify ASCs. In addition, the work also demonstrates the 
potential of genetically modified ASCs for successful xeno-
transplantation applications.
Using a hybrid model of TAT/DNAAng1 NPs coupled to 
BacAng1 for ASC transduction under optimized conditions 
(Figure S1), significantly higher gene transfer efficiency and 
gene carrying capacity was achieved than free BacAng1 or NP Ang1 
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Figure 8 Echocardiographic assessment of cardiac function. Effect of hASC-Ang1 transplantation on cardiac function was analyzed over 28 days post-infarction. Heart 
ejection fraction was monitored on days three, 14, and 28 after transplantation of medium (n = 8), hASCs (n = 8), and hASC-Ang1 (n = 8) in rat myocardial infarction model 
using M-mode echocardiograms (i–iii represents data of day 28). (B) As demonstrated in the graph, ejection fraction increased significantly after treatment in the hASC-Ang1 
and hASC groups over the 28 days post-infarction, but the untreated control group did not show any sign of improvement. Ejection fraction was significantly higher in the 
treated groups compared to the control on days 14 and 28 after treatment. Furthermore, hASC-Ang1 group showed a significantly better ejection fraction than hASC group 
with time.
Notes: Mean ejection fraction ± standard deviation is shown in graph. Echocardiogram analysis two-way analysis of variance: F = 13.28, P = 0.0002 (treatment groups); 
F = 77.95, P , 0.0001 (time); F = 28.47, P , 0.0001 (interaction); F = 9.716, P , 0.0001 (subjects matching); ***P , 0.001; **P , 0.01; *P , 0.05 versus time-matched control. 
†P , 0.01 versus time-matched hASC.
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alone (Figure 2 and Figure S2). Figure S2 demonstrates that 
Bac-NP, with Bac MOI of 200 and N/P ratio (defined as the 
molar ratio of amino groups/phosphate groups) of 3 of TAT/
DNA NP, was optimal so as to achieve the highest transduc-
tion efficiency with no cytotoxic effects (Figure S3). Data 
also confirm that gene transfer efficiency can be significantly 
enhanced by this hybrid nanoformulation of Bac and NP, as 
compared to their individual efficiencies. In vitro analysis 
showed that Bac-NP-transduced cells were able to express their 
transgene for at least 3 weeks (Figure 2C), which is comparable 
to other experimental results.24,31 This temporal expression of 
the delivery system is beneficial in many cases, particularly for 
angiogenesis where the expression of the therapeutic protein 
ceases once its job is done. Further studies need to be done 
to comprehend the exact mechanism of such a gene delivery 
  system. Rapid attachment of cationic NPs to a negatively 
charged cell surface followed by efficient intracellular gene 
entry to the nucleus by Bac may be a probable way. Optimizing 
the pH condition and transduction time may further enhance 
the gene delivery efficiency of the Bac-NP system.10
Bac surface modification by chemical coupling and elec-
trostatic interactions is recently being exploited in different 
ways for enhanced gene delivery.32 It has been demonstrated 
that galactosylated polyethylenimine/DNA hybridized Bac 
improves gene delivery to hepatoblastoma and lung carci-
noma cells.33 Coating of Bac using positively charged poly-
mer polyethylenimine is also shown to significantly enhance 
their in vivo gene therapy potential compared to uncoated 
viruses.34 Recently Chen et al demonstrated that genetically 
modified Bac generated by fusing the protein transduction 
domain of human immunodeficiency virus TAT protein with 
VP39, the major capsid protein, resulted in improved trans-
duction of various mammalian cells.35 Similarly, the present 
study demonstrates that surface modifying Bac with TAT/
DNA NPs can also improve gene transfer efficiency. But, 
to achieve significant therapeutic effects, specifically with 
stem cells, maintenance of their natural functionalities is of 
immense importance. The present study confirmed this by 
successfully differentiating the genetically modified hASCs 
to adipogenic and osteogenic lineages (Figure S4). In addi-
tion, data revealed that Bac-NP-mediated hAng1 expression 
from hASCs were biologically active as indicated by their 
enhanced mitotic and chemotactic activities on HUVEC 
(Figure 3). The study also confirmed that the released Ang1 
possesses antiapoptotic and protective effects on cardiomyo-
cytes (Figure 4). This supports the findings reported by Wang 
et al who reported that Ang1 can protect cardiomyocytes from 
oxidative stress-induced apoptosis.25
In addition to efficient transgene expression, retention of 
viability of transplanted cells at the infarct site is an important 
parameter that determines the myocardial therapeutic index 
of the study. This is because higher retention of viable cells 
directly correlates with enhanced secretion of paracrine fac-
tors and better scope for cellular cardiomyoplasty. Previous 
works have aimed to address this problem using polymeric 
microcapsules to reduce the biologic and mechanical loss 
of implanted cells in the continuously beating heart.11,14,36 In 
an interesting study, Liu et al demonstrated that Ang1 can 
protect MSC against serum deprivation and hypoxia-induced 
apoptosis.37 Detection of a significantly higher amount of 
human Y chromosome-positive hASCs in recipient female rat 
hearts treated with hASC-Ang1 compared to hASC, 28 days 
post-implantation, confirmed these findings (Figure 5B).
Most importantly, hASC-Ang1 treatment resulted in 
enhancement of vascular density (Figure 7), thereby sig-
nificantly improving cardiac function (Figure 8) compared 
to hASC and control groups; although cardiomyogenic 
transdifferentiation of grafted cells was not detected in any 
of the groups.6 Moreover, histological findings confirmed the 
reduction of fibrosis in the infarct area (Figure 6), which is 
an important indicator for improved heart function since late 
reperfusion of infarcted vascular beds attenuates left ventricu-
lar remodeling including infarct expansion.4 Measurement of 
blood flow using cardiac magnetic resonance imaging-based 
techniques can give a better real time picture on the progress of 
such myocardial regenerative process post cell transplantation. 
Although preclinical findings exemplify the beneficial effects 
of such combined adipose stem cell-gene therapy treatment, 
further in vivo studies are needed to elucidate the precise 
mechanism and to investigate its prolonged effects on cardiac 
function; these will help determine whether one-time cell deliv-
ery is a viable option or whether multiple cell transplantations 
are required to achieve a long term desirable outcome.
Conclusion
From a clinical standpoint, the study promises major 
advancements where ASCs could be easily harvested and 
mass produced well in advance, genetically modified to 
express biologically active therapeutic proteins, and stored 
for immediate off-the-shelf use on any patient without delay 
after an acute myocardial infarction.
In summary, it was demonstrated that a hybrid nanodelivery 
complex of Bac and NPs can take advantage of the unique 
features associated with the two individual vector systems and 
exhibit enhanced gene transfer efficiency,   supported by in vitro 
and in vivo experimental   demonstrations. It was illustrated that 
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genetically-engineered hASCs, using a hybrid nanocomplex, 
enhanced the transplant retention in a myocardially infarcted 
rat model and induced a significant favorable impact on tis-
sue perfusion and contractile performance, which have been 
corroborated with vasculogenesis. Taken together, the current 
findings confirm the feasibility of a combined stem cell-based 
gene therapy for ischemic heart diseases using a novel, biologi-
cally safe nanobiohybrid gene delivery system.
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Supplementary information
Characterization of baculovirus (Bac)-
nanoparticle (NP) hybrid complex
The particle size and zeta potential of the NP, Bac, and 
Bac-NP hybrid particles were measured by the technique 
of electrophoretic laser Doppler anemometry using a Zeta 
Potential Analyzer (ZetaPlus; Brookhaven Instruments 
  Corporation, Holtsville, NY). ZetaPlus Particle Sizer 
  Software (v 4.11; Brookhaven) was used to determine the 
size distribution of the particles and Zeta Potential Analyzer 
software (v 3.57; Brookhaven) was used for zeta potential 
analysis. Both particle size and zeta potential were measured 
for three independent preparations and each measurement 
was obtained after taking the average of the three runs. 
Transmission electron microscopy (TEM) was used to 
obtain the size characterization. The NPs were suspended in 
1× phosphate buffered saline and analyzed on CM200 FEG-
TEM (Royal Philips Electronics, Markham, ON, Canada). 
Results are presented in Figure S1.
The scanning electron microscope (SEM; S4700 FEG-
SEM Hitachi, Oakville, ON, Canada) and atomic force 
microscope (AFM; Digital Instruments, Palo Alto, CA) photo-
micrographs in Figure 2A and B confirm the formation of NP 
by transactivating transcriptional activator (TAT) and DNA 
complexation. The formed NPs were further studied by TEM 
and zeta potential analyzer, as demonstrated in Figure S1C–F. 
The Bac-NP complex was first characterized by measuring the 
zeta potential of the nanocomplex with laser Doppler electro-
phoresis (Figure S1C). At its natural pH 6.8, Bac is negatively 
charged with zeta potential of −6.5 ± 1.4 mV . At physiological 
pH 7.4, Bac had a zeta potential of −12.8 ± 3.1 mV . On the 
other hand, prepared TAT/DNA NPs showed high positive 
charge of 26.5 ± 3.2 mV at N/P ratio of 3. The positively 
charged TAT/DNA NPs, upon conjugation with the nega-
tively charged Bac, formed positively charged (5.1 ± 2.7 mV) 
Bac-NP hybrid nanocomplexes.
To reconfirm the successful formation of the Bac-NP com-
plexes, particle sizes of each complex were measured. Free Bac 
had an average size of 238 ± 10 nm, whereas free TAT/DNA 
NP showed an average size of around 72 ± 4.6 nm. The Bac-NP 
hybrid complexes had an average size of 480 ± 18.2 nm. This 
significant increase in size of Bac-NP particles, compared to 
that of free Bac and NPs, indicates the efficient production of 
the nanobiohybrid complexes, generated by strong electrostatic 
interactions of Bac with the NPs.
In order to look for the morphological evidence for 
successful conjugation of the budded Bac particles with 
the NPs, TEM was used. Electron micrographs showed the 
well-dispersed NPs (Figure S1D). On coming in contact with 
free Bac (Figure S1E; the rod-shaped particles with a length 
of 200–250 nm), there was an instant virus-NP complex 
formation by the negatively charged Bac with the positively 
charged NP, as indicated in Figure S1F to form the hybrid-
ized Bac-NP complex. The images of Bac-NP complexes 
also confirm the proper retention of the typical rod-shaped 
morphological appearance and envelope structure of Bac, 
suggesting that Bac were able to sustain their morphological 
integrity even after hybridization with NPs.
Optimization of viral dose for Bac-NP 
mediated human adipose tissue-derived 
stem cell (hASC) transduction
In order to achieve maximum transduction, the effect of 
multiplicity of infection (defined as plaque forming units per 
cell) and their combinatorial effects on the hybrid Bac-NP 
system were optimized. For this, multiplicity of infection 
ranging from 100 to 400 and N/P ratio of 3 were used. 
Initially, hASCs were seeded in six-well plates at 0.5 × 106 
cells/well and incubated overnight at 5% carbon dioxide and 
37°C. Following this, an appropriate volume of transduction 
solutions from different experimental groups (LacZ-carrying 
Bac, LacZ-carrying NP, Bacnull-LacZ-carrying NP, LacZ-
carrying Bac, LacZ-carrying NP, LacZ-carrying Bac-NPnull), 
suspended in phosphate buffered saline, was added to each 
well according to varied multiplicity of infection, and incu-
bated for 4 hours at 25°C. Bacnull and NPnull represent delivery 
systems carrying DNA with no gene of interest. The wells 
were replenished with fresh media and grown 37°C in carbon 
dioxide incubator. After 24 hours, the cells were stained with 
X-gal to detect the transduced LacZ-expressing cells. Results 
are presented in Figure S2.
Bac-NP has no toxic effects on hASCs: 
cytotoxicity assay
For the cytotoxicity assay, 2 × 104 hASCs/well were seeded 
in triplicate for each sample in 96-well plates. After cultur-
ing overnight, the cells were washed twice with phosphate 
buffered saline. NP, Bac, and Bac-NP particles suspended 
in culture media (200 µL) were added to the corresponding 
set of wells. Nontransduced cells were used as control. After 
24 hours, absorbance of each well were measured at 490 nm 
using CellTiter® 96 AQueous Non-Radioactive Cell Prolif-
eration Assay (Promega, Fitchburg, WI) in a plate reader. 
The percentage of viable cells in different experimental 
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Figure S1 Characterization of the Bac-NP hybrid nanocomplex. (A) Scanning electron microscope photograph of transactivating transcriptional activator/deoxyribonucleic 
acid nanoparticles with subset showing a magnified image. (B) Atomic force microscope photograph of NPs demonstrating their surface topography. (C) Zeta potential of free 
Bac at pH 6.8 (pH of insect cells media), free Bac at pH 7.4 (pH of mammalian cell culture), free NP (phosphate buffered saline: pH 7.4), and hybrid Bac-NP nanocomplexes at 
pH 7.4, with N/P ratio of 3. The complexes were prepared from 1 µg deoxyribonucleic acid (complexed with transactivating transcriptional activator) per 109 plaque forming 
units Bac. Transmission electron microscope images of (D) NP with N/P ratio of 3, (E) Bac, and (F) Bac-NP suspended in phosphate buffered saline.
Notes: Arrows indicate NPs hybridized on Bac surface. Scale bar: 100 nm.
Abbreviations: Bac, baculovirus; Bac-NP, baculovirus-nanoparticle complex; NP, nanoparticle.International Journal of Nanomedicine 2012:7
groups was quantified. All the experiments were performed 
in triplicate. Results are presented in Figure S3.
Bac-NP transduced hASCs retain  
their differentiation potential
Bac-NP-transduced hASCs were then seeded in a 24-well plate 
at a high confluency of 6 × 104 cells/well.   Nontransduced cells 
were used as control. After 24 hours, the medium was replaced 
with either adipogenic or osteogenic differentiation medium 
(Invitrogen Life Technologies, Carlsbad, CA). Osteogenic 
differentiation was assessed using Alizarin Red S staining 
(  Invitrogen) after a 21-day period of induction towards this 
lineage. After a 15-day period, adipogenic differentiation was 
evaluated by LipidTOX™ red neutral lipid staining (Invitro-
gen). Results are presented in Figure S4. The presence of cal-
cium deposits following osteogenic induction, as well as lipid 
vacuoles following adipogenic induction, is indicative of the 
transduced hASCs’ ability for multilineage differentiation.
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Figure S2 Optimization of transduction condition in human adipose tissue-derived stem cells with Bac-NPLacZ. In each well of 96-well plate, 2 × 104 cells were seeded and 
cultured overnight. The nanobiohybrid complexes were prepared from 1 µg deoxyribonucleic acid (complexed with transactivating transcriptional activator) per 109 plaque 
forming units baculovirus. Effect of baculovirus MOI on baculovirus-nanoparticle complex-mediated cell transduction. Cells were transduced with the prepared baculovirus-
nanoparticle complex at constant N/P ratio of 3 with MOI of 100, 200, and 400 and stained with X-gal, 24 hours post-transduction, to determine the percentage cells 
transduced with LacZ expression. Three independent experiments were performed and data expressed as mean ± standard deviation. Bac-NPLacZ with MOI of 200 showed 
highest transduction as compared to other groups.
Abbreviations: BacLacZ, LacZ-carrying baculovirus; BacLacz-NPnull, LacZ-carrying baculovirus-nanoparticle (carrying no gene of interest) complex; Bac-NPLacZ, baculovirus-
LacZ-carrying nanoparticle complex; Bacnull-NPLacZ, baculovirus (carrying no gene of interest)-LacZ-carrying nanoparticle complex; MOI, multiplicity of infection.
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Figure S3 Cytotoxic effects of baculovirus-nanoparticle hybrid complexes on human adipose tissue-derived stem cells. In each well of 96-well plate, 2 × 104 cells were seeded 
and cultured overnight. The cells were incubated with nanoparticles (N/P ratio 3) only, baculovirus (multiplicity of infection 200) only, and baculovirus-nanoparticle complex 
(multiplicity of infection 200 and N/P ratio 3) for 12 hours followed by cell toxicity analysis.
Notes: Three independent experiments were performed and data expressed as mean ± standard deviation. There were no significant differences in percentage viability 
between the groups, confirming that the baculovirus-nanoparticle complex did not have any toxic effect on the human adipose tissue-derived stem cells.
Abbreviations: BacLacZ, LacZ-carrying baculovirus; BacLacZ-NPLacZ, LacZ-carrying baculovirus-LacZ-carrying nanoparticle complex; BacLacz-NPnull, LacZ-carrying baculovirus-
nanoparticle (carrying no gene of interest) complex; Bacnull-NPLacZ, baculovirus (carrying no gene of interest)-LacZ-carrying nanoparticle complex; NPLacZ, LacZ-carrying 
nanoparticle.International Journal of Nanomedicine
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Figure S4 Adipogenic and osteogenic differentiation of baculovirus-nanoparticle complex-transduced human adipose tissue-derived stem cells. Transduced adipose tissue-
derived stem cells were cultured in either adipogenic or osteogenic differentiation media. Adipogenic differentiation was assessed via LipidTOX™ Red neutral lipid staining 
of lipid vacuoles and 4′,6-diamidino-2-phenylindole staining of nucleus: (i) transduced differentiated and (ii) nontransduced differentiated. Osteogenic differentiation was 
determined by Alizarin Red staining of calcium deposits: (i) transduced differentiated and (ii) nontransduced differentiated.
Notes: Arrows show the cell differentiated area. Results confirm that human adipose tissue-derived stem cells retain their multilineage differential potential even after 
baculovirus-nanoparticle complex transduction.